Reported Earnings • Aug 07
First quarter 2027 earnings released: ₹0.75 loss per share (vs ₹0.38 loss in 1Q 2026) First quarter 2027 results: ₹0.75 loss per share (further deteriorated from ₹0.38 loss in 1Q 2026). Revenue: ₹951.7m (up 33% from 1Q 2026). Net loss: ₹40.2m (loss widened 114% from 1Q 2026). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Announcement • Aug 01
ZIM Laboratories Limited to Report Q1, 2027 Results on Aug 06, 2026 ZIM Laboratories Limited announced that they will report Q1, 2027 results on Aug 06, 2026 New Risk • Jun 11
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 44% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 2.9% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.6% net profit margin). Market cap is less than US$100m (₹5.97b market cap, or US$62.4m). Announcement • Jun 09
ZIM Laboratories Limited, Annual General Meeting, Jun 29, 2026 ZIM Laboratories Limited, Annual General Meeting, Jun 29, 2026, at 11:30 Indian Standard Time. Reported Earnings • May 21
Full year 2026 earnings released: EPS: ₹1.19 (vs ₹2.50 in FY 2025) Full year 2026 results: EPS: ₹1.19 (down from ₹2.50 in FY 2025). Revenue: ₹3.86b (up 1.8% from FY 2025). Net income: ₹58.4m (down 52% from FY 2025). Profit margin: 1.5% (down from 3.2% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Announcement • May 12
ZIM Laboratories Limited to Report Q4, 2026 Results on May 19, 2026 ZIM Laboratories Limited announced that they will report Q4, 2026 results on May 19, 2026 Valuation Update With 7 Day Price Move • May 08
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹103, the stock trades at a trailing P/E ratio of 79x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 15% over the past three years. Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹83.81, the stock trades at a trailing P/E ratio of 64.2x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 7.1% over the past three years. Announcement • Mar 13
ZIM Laboratories Limited announced that it has received INR 349.99995 million in funding from Florintree Trinex LLP On March 13, 2026, ZIM Laboratories Limited closed the transaction. The transaction has been approved by the board of directors. Reported Earnings • Feb 13
Third quarter 2026 earnings released: EPS: ₹0.90 (vs ₹0.82 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.90 (up from ₹0.82 in 3Q 2025). Revenue: ₹1.09b (up 13% from 3Q 2025). Net income: ₹44.0m (up 9.9% from 3Q 2025). Profit margin: 4.0% (down from 4.2% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Announcement • Feb 05
ZIM Laboratories Limited to Report Q3, 2026 Results on Feb 11, 2026 ZIM Laboratories Limited announced that they will report Q3, 2026 results on Feb 11, 2026 Announcement • Jan 21
ZIM Laboratories Limited announced that it expects to receive INR 349.99995 million in funding ZIM Laboratories Limited announced a private placement of 4,764,497 Equity Shares of the company at an issue price of INR 73.46 for gross proceeds of INR 349,999,949.62 by way of preferential basis on January 21, 2026. The transaction involves participation from new investor Florintree Trinex LLP to purchase 4,764,497 Equity Shares of the company to attain Post-Preferential Issue holding of 8.91% of the company. The transaction has been approved by Board of the company and is subject to approval by the shareholders’ approval and such other regulatory/ statutory/governmental approvals as may be required. The transaction has been issued in accordance with the provisions of the Companies Act, 2013 and the rules made thereunder, Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable laws. The Board has approved the convening of an extra-ordinary general meeting of the shareholders of the Company on 16th February, 2026 for seeking shareholders’ approval for the Preferential Issue. The Board approved the draft of the EGM notice and other related matters. The notice for the said EGM shall be submitted to the stock exchanges in due course in compliance with applicable provisions of the Listing Regulations. New Risk • Jan 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Share price has been highly volatile over the past 3 months (8.4% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (1.8% net profit margin). Market cap is less than US$100m (₹3.87b market cap, or US$42.6m). Valuation Update With 7 Day Price Move • Jan 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹79.39, the stock trades at a trailing P/E ratio of 58.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 9.8% over the past three years. Reported Earnings • Nov 14
Second quarter 2026 earnings released: ₹0.09 loss per share (vs ₹0.49 profit in 2Q 2025) Second quarter 2026 results: ₹0.09 loss per share (down from ₹0.49 profit in 2Q 2025). Revenue: ₹907.5m (down 1.5% from 2Q 2025). Net loss: ₹4.25m (down 118% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Announcement • Nov 05
ZIM Laboratories Limited to Report Q2, 2026 Results on Nov 12, 2025 ZIM Laboratories Limited announced that they will report Q2, 2026 results on Nov 12, 2025 Reported Earnings • Aug 08
First quarter 2026 earnings released: ₹0.38 loss per share (vs ₹0.18 profit in 1Q 2025) First quarter 2026 results: ₹0.38 loss per share (down from ₹0.18 profit in 1Q 2025). Revenue: ₹732.3m (down 11% from 1Q 2025). Net loss: ₹18.7m (down 309% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. New Risk • Aug 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 6.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Share price has been highly volatile over the past 3 months (6.1% average weekly change). Minor Risks Profit margins are more than 30% lower than last year (3.2% net profit margin). Market cap is less than US$100m (₹5.26b market cap, or US$60.1m). Valuation Update With 7 Day Price Move • Aug 04
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₹86.30, the stock trades at a trailing P/E ratio of 34.6x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 22% over the past three years. Announcement • Aug 02
ZIM Laboratories Limited to Report Q1, 2026 Results on Aug 07, 2025 ZIM Laboratories Limited announced that they will report Q1, 2026 results on Aug 07, 2025 Announcement • Jul 21
ZIM Laboratories Limited Receives First Marketing Authorization in Australia for Rizatriptan Benzoate Orally Disintegrating Films Via Zimtas Pty Ltd ZIM Laboratories Limited announced that the Therapeutic Goods Administration (TGA), Australia has granted Marketing Authorization (MA) for its Central Nervous System (CNS) product "Rizatriptan Benzoate Orally Disintegrating Films" through its Australian Subsidiary, ZIMTAS. This approval marks ZIM's first Marketing Authorization in Australia and represents an important milestone in the Company's strategy to expand its presence in regulated markets through innovative drug delivery technologies. Rizatriptan, a selective 5-HT1B/1D receptor agonist, is indicated for the acute treatment of migraine attacks, with or without aura, in adults. The orally disintegrating film (ODF) formulation developed using ZIM's proprietary technology platform offers a patient-friendly alternative that enables rapid onset of action without the need for water, making it especially convenient for patients experiencing nausea or vomiting during migraine episodes. Announcement • Jun 28
Zim Laboratories Limited Approves to Appoint of Ashok Bhatia as an Independent Director ZIM Laboratories Limited at the AGM held on June 27, 2025, approved to appoint of Mr. Ashok Bhatia as an Independent Director of the company. Valuation Update With 7 Day Price Move • Jun 10
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹105, the stock trades at a trailing P/E ratio of 42.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 48% over the past three years. Announcement • May 23
ZIM Laboratories Limited, Annual General Meeting, Jun 27, 2025 ZIM Laboratories Limited, Annual General Meeting, Jun 27, 2025, at 11:30 Indian Standard Time. New Risk • May 21
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.6x net interest cover). Minor Risks Profit margins are more than 30% lower than last year (3.2% net profit margin). Market cap is less than US$100m (₹4.59b market cap, or US$53.6m). Announcement • May 14
ZIM Laboratories Limited to Report Fiscal Year 2025 Results on May 20, 2025 ZIM Laboratories Limited announced that they will report fiscal year 2025 results on May 20, 2025 Reported Earnings • Feb 11
Third quarter 2025 earnings released: EPS: ₹0.82 (vs ₹0.98 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.82 (down from ₹0.98 in 3Q 2024). Revenue: ₹980.8m (up 1.9% from 3Q 2024). Net income: ₹40.0m (down 16% from 3Q 2024). Profit margin: 4.1% (down from 5.0% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Announcement • Feb 03
ZIM Laboratories Limited to Report Q3, 2025 Results on Feb 10, 2025 ZIM Laboratories Limited announced that they will report Q3, 2025 results on Feb 10, 2025 Reported Earnings • Nov 10
Second quarter 2025 earnings released: EPS: ₹0.49 (vs ₹0.85 in 2Q 2024) Second quarter 2025 results: EPS: ₹0.49 (down from ₹0.85 in 2Q 2024). Revenue: ₹934.6m (up 8.9% from 2Q 2024). Net income: ₹23.8m (down 43% from 2Q 2024). Profit margin: 2.5% (down from 4.8% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Nov 05
ZIM Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024 ZIM Laboratories Limited announced that they will report Q2, 2025 results on Nov 09, 2024 Reported Earnings • Aug 04
First quarter 2025 earnings released: EPS: ₹0.18 (vs ₹0.05 in 1Q 2024) First quarter 2025 results: EPS: ₹0.18 (up from ₹0.05 in 1Q 2024). Revenue: ₹828.2m (up 23% from 1Q 2024). Net income: ₹8.98m (up 296% from 1Q 2024). Profit margin: 1.1% (up from 0.3% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 27
ZIM Laboratories Limited to Report Q1, 2025 Results on Aug 08, 2024 ZIM Laboratories Limited announced that they will report Q1, 2025 results on Aug 08, 2024 Announcement • Jun 06
ZIM Laboratories Limited, Annual General Meeting, Jun 27, 2024 ZIM Laboratories Limited, Annual General Meeting, Jun 27, 2024, at 11:30 Indian Standard Time. Reported Earnings • May 14
Full year 2024 earnings released: EPS: ₹3.54 (vs ₹5.02 in FY 2023) Full year 2024 results: EPS: ₹3.54 (down from ₹5.02 in FY 2023). Revenue: ₹3.73b (down 6.5% from FY 2023). Net income: ₹172.5m (down 29% from FY 2023). Profit margin: 4.6% (down from 6.1% in FY 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 08
ZIM Laboratories Limited to Report Q4, 2024 Results on May 13, 2024 ZIM Laboratories Limited announced that they will report Q4, 2024 results on May 13, 2024 Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹111, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 248% over the past three years. Buy Or Sell Opportunity • Apr 23
Now 34% overvalued after recent price rise Over the last 90 days, the stock has risen 1.3% to ₹111. The fair value is estimated to be ₹83.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Earnings per share has grown by 38%. Buy Or Sell Opportunity • Apr 05
Now 22% overvalued Over the last 90 days, the stock has fallen 13% to ₹101. The fair value is estimated to be ₹83.07, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Earnings per share has grown by 38%. Buy Or Sell Opportunity • Mar 14
Now 23% overvalued Over the last 90 days, the stock has fallen 6.2% to ₹102. The fair value is estimated to be ₹82.91, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Earnings per share has grown by 38%. Reported Earnings • Jan 30
Third quarter 2024 earnings released: EPS: ₹0.98 (vs ₹1.35 in 3Q 2023) Third quarter 2024 results: EPS: ₹0.98 (down from ₹1.35 in 3Q 2023). Revenue: ₹974.0m (down 3.5% from 3Q 2023). Net income: ₹47.8m (down 28% from 3Q 2023). Profit margin: 4.9% (down from 6.5% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 56% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 23
ZIM Laboratories Limited to Report Q3, 2024 Results on Jan 29, 2024 ZIM Laboratories Limited announced that they will report Q3, 2024 results on Jan 29, 2024 Reported Earnings • Nov 03
Second quarter 2024 earnings released: EPS: ₹0.85 (vs ₹1.12 in 2Q 2023) Second quarter 2024 results: EPS: ₹0.85 (down from ₹1.12 in 2Q 2023). Revenue: ₹872.5m (down 12% from 2Q 2023). Net income: ₹41.5m (down 24% from 2Q 2023). Profit margin: 4.8% (down from 5.5% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Oct 21
ZIM Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023 ZIM Laboratories Limited announced that they will report Q2, 2024 results on Nov 01, 2023 Reported Earnings • Aug 15
First quarter 2024 earnings released: EPS: ₹0.05 (vs ₹1.06 in 1Q 2023) First quarter 2024 results: EPS: ₹0.05 (down from ₹1.06 in 1Q 2023). Revenue: ₹685.6m (down 26% from 1Q 2023). Net income: ₹2.27m (down 96% from 1Q 2023). Profit margin: 0.3% (down from 5.6% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 05
ZIM Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023 ZIM Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₹149, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 307% over the past three years. Valuation Update With 7 Day Price Move • Jul 17
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹121, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 273% over the past three years. Announcement • Jun 29
ZIM Laboratories Limited (BSE:541400) agreed to acquire 99% stake in Zimtas Pty Ltd for approximately AUD 0.01 million. ZIM Laboratories Limited (BSE:541400) agreed to acquire 99% stake in Zimtas Pty Ltd for approximately AUD 0.01 million on June 28, 2023. New Risk • Jun 28
New major risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₹5.50b market cap, or US$67.1m). Announcement • Jun 17
ZIM Laboratories Limited, Annual General Meeting, Jul 10, 2023 ZIM Laboratories Limited, Annual General Meeting, Jul 10, 2023, at 11:30 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31 March, 2023 and the report of the Board of Directors and Auditors thereon; to consider Re-appointment of Director in place of retiring Director; and to consider Ratification of remuneration payable to M/s Dhananjay V. Joshi & Associates, Cost Auditors, for the Financial Year 2023-24. Reported Earnings • May 21
Full year 2023 earnings released: EPS: ₹5.01 (vs ₹2.99 in FY 2022) Full year 2023 results: EPS: ₹5.01 (up from ₹2.99 in FY 2022). Revenue: ₹4.05b (up 21% from FY 2022). Net income: ₹244.3m (up 68% from FY 2022). Profit margin: 6.0% (up from 4.4% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 15
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₹98.35, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 368% over the past three years. Reported Earnings • Feb 05
Third quarter 2023 earnings released: EPS: ₹1.35 (vs ₹0.84 in 3Q 2022) Third quarter 2023 results: EPS: ₹1.35 (up from ₹0.84 in 3Q 2022). Revenue: ₹1.01b (up 16% from 3Q 2022). Net income: ₹66.0m (up 62% from 3Q 2022). Profit margin: 6.5% (up from 4.7% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 52% per year, which means it is significantly lagging earnings growth. Announcement • Jan 26
ZIM Laboratories Limited to Report Q3, 2023 Results on Feb 03, 2023 ZIM Laboratories Limited announced that they will report Q3, 2023 results on Feb 03, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹3.35 (vs ₹2.00 in 2Q 2022) Second quarter 2023 results: EPS: ₹3.35 (up from ₹2.00 in 2Q 2022). Revenue: ₹1.01b (up 30% from 2Q 2022). Net income: ₹54.5m (up 67% from 2Q 2022). Profit margin: 5.4% (up from 4.2% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has increased by 59% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Nov 08
Investor sentiment improved over the past week After last week's 17% share price gain to ₹294, the stock trades at a trailing P/E ratio of 24.5x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 258% over the past three years. Announcement • Nov 06
ZIM Laboratories Limited to Report Q4, 2022 Results on Nov 12, 2022 ZIM Laboratories Limited announced that they will report Q4, 2022 results at 12:15 PM, Indian Standard Time on Nov 12, 2022 Valuation Update With 7 Day Price Move • Aug 30
Investor sentiment improved over the past week After last week's 24% share price gain to ₹262, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 137% over the past three years. Announcement • Aug 25
ZIM Laboratories Limited, Annual General Meeting, Sep 19, 2022 ZIM Laboratories Limited, Annual General Meeting, Sep 19, 2022, at 12:30 Indian Standard Time. Reported Earnings • Jul 27
First quarter 2023 earnings released: EPS: ₹3.17 (vs ₹0.12 in 1Q 2022) First quarter 2023 results: EPS: ₹3.17 (up from ₹0.12 in 1Q 2022). Revenue: ₹946.4m (up 48% from 1Q 2022). Net income: ₹51.5m (up ₹49.6m from 1Q 2022). Profit margin: 5.4% (up from 0.3% in 1Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 28% per year whereas the company’s share price has increased by 32% per year. Announcement • Jul 20
ZIM Laboratories Limited to Report Q1, 2023 Results on Jul 26, 2022 ZIM Laboratories Limited announced that they will report Q1, 2023 results on Jul 26, 2022 Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improved over the past week After last week's 19% share price gain to ₹214, the stock trades at a trailing P/E ratio of 23.9x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 87% over the past three years. Board Change • May 31
High number of new directors Additional Independent Director Kakasaheb Mahadik was the last director to join the board, commencing their role in 2022. Reported Earnings • May 26
Full year 2022 earnings released: EPS: ₹8.96 (vs ₹4.51 in FY 2021) Full year 2022 results: EPS: ₹8.96 (up from ₹4.51 in FY 2021). Revenue: ₹3.33b (up 8.5% from FY 2021). Net income: ₹145.5m (up 99% from FY 2021). Profit margin: 4.4% (up from 2.4% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • May 24
Investor sentiment improved over the past week After last week's 17% share price gain to ₹234, the stock trades at a trailing P/E ratio of 42x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 88% over the past three years. Announcement • May 16
ZIM Laboratories Limited to Report Q4, 2022 Results on May 21, 2022 ZIM Laboratories Limited announced that they will report Q4, 2022 results on May 21, 2022 Board Change • Apr 27
High number of new directors Additional Independent Director Kakasaheb Mahadik was the last director to join the board, commencing their role in 2022. Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improved over the past week After last week's 27% share price gain to ₹205, the stock trades at a trailing P/E ratio of 36.8x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 66% over the past three years. Announcement • Apr 01
ZIM Laboratories Limited Announces Board Changes, Effective April 1, 2022 ZIM Laboratories Limited have approved the appointment of Dr. Kamlesh Shende and Dr. Kakasaheb Mahadik as Additional Directors (Independent Directors) on the Board of the Company with effect from 1st April, 2022 . The aforesaid appointments are subject to the approval of the members in the General Meeting. It is further informed that the second tenure of Dr. Naresh Gaikwad, Dr. Veerendra Parashar and Mr. Suprakash Chakravarty as Independent Directors, would be completing on 31st March, 2022 and therefore, they would cease to be Independent Directors of the Company with effect from 01st April, 2022. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment improved over the past week After last week's 15% share price gain to ₹169, the stock trades at a trailing P/E ratio of 43.7x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 17% over the past three years. Reported Earnings • Nov 01
Second quarter 2022 earnings released: EPS ₹2.00 (vs ₹0.73 in 2Q 2021) The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2022 results: Revenue: ₹783.4m (down 11% from 2Q 2021). Net income: ₹32.6m (up 173% from 2Q 2021). Profit margin: 4.2% (up from 1.4% in 2Q 2021). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 18
First quarter 2022 earnings released: EPS ₹0.12 (vs ₹2.02 in 1Q 2021) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹654.0m (down 7.2% from 1Q 2021). Net income: ₹1.89m (down 94% from 1Q 2021). Profit margin: 0.3% (down from 4.7% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Executive Departure • Jul 13
Director of Administration & Executive Director Riaz Ahmed Kamal has left the company On the 1st of July, Riaz Ahmed Kamal's tenure as Director of Administration & Executive Director ended after 23.5 years in the role. We don't have any record of a personal shareholding under Riaz Ahmed's name. Riaz Ahmed is the only executive to leave the company over the last 12 months. Announcement • Jul 03
Zim Laboratories Limited Announces Granting of Marketing Authorization for Rizatriptan Orally Dissolving Film in Portugal ZIM Laboratories Limited announced that Infarmed has granted marketing authorization for its innovative product, Rizatriptan Orally Dissolving Film in Portugal, Europe to its wholly-owned European subsidiary. Rizatriptan is widely used for relief from Migraine attacks. Migraine was ranked as the fifth leading cause of years lived with disability (YLD) in Western Europe and the sixth leading cause of YLD in Central and Eastern Europe in the Global Burden of Disease1. The economic burden of migraine is significant. Different European studies have estimated the cost of migraine at 18 billion to 27 billion depending on study setting and design. The majority of all migraine-related costs (7793%) are indirect costs attributed primarily to work productivity losses2. Migraine is often associated with symptoms such as nausea, vomiting, phonophobia (sensitivity to sound), and photophobia (sensitivity to light) and because of the severity of the symptoms it needs medication that can be given to patient without making these symptoms worse and that also produces a faster onset of action. Rizatriptan Orally Dissolving Film is a product developed using Thinoral® technology which yields instantly wettable, rapidly dissolving, and stable films. The fast dissolving feature provides potentially faster onset of action, and the flexible nature of film dosage allows for convenience in handling and administration. As the presently available product in the market is a mouth dissolving tablet which is extremely fragile, Zim's product offering is likely to provide significant advantage to patients in terms of portability as well as faster action. Rizatriptan orally dissolving film by virtue of its convenience in administration ensures treatment adherence and will help to reduce economic burden. The global market of Rizatriptan is about 200 million USD. Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment improved over the past week After last week's 21% share price gain to ₹116, the stock trades at a trailing P/E ratio of 25.9x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total loss to shareholders of 34% over the past three years. Reported Earnings • Jun 02
Full year 2021 earnings released: EPS ₹4.50 (vs ₹2.04 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.10b (up 11% from FY 2020). Net income: ₹73.2m (up 122% from FY 2020). Profit margin: 2.4% (up from 1.2% in FY 2020). Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improved over the past week After last week's 29% share price gain to ₹97.40, the stock trades at a trailing P/E ratio of 19.6x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past year. Reported Earnings • Feb 12
Third quarter 2021 earnings released: EPS ₹0.80 (vs ₹0.94 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹756.1m (up 3.1% from 3Q 2020). Net income: ₹12.9m (down 15% from 3Q 2020). Profit margin: 1.7% (down from 2.1% in 3Q 2020). Is New 90 Day High Low • Feb 11
New 90-day low: ₹79.75 The company is down 14% from its price of ₹93.00 on 13 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. Announcement • Feb 06
ZIM Laboratories Limited to Report Nine Months, 2021 Results on Feb 11, 2021 ZIM Laboratories Limited announced that they will report nine months, 2021 results on Feb 11, 2021 Is New 90 Day High Low • Jan 25
New 90-day low: ₹85.00 The company is down 14% from its price of ₹99.00 on 27 October 2020. The Indian market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Reported Earnings • Oct 27
First half earnings released Over the last 12 months the company has reported total profits of ₹82.9m, up 8.8% from the prior year. Total revenue was ₹3.00b over the last 12 months, down 8.3% from the prior year. Valuation Update With 7 Day Price Move • Oct 22
Market bids up stock over the past week After last week's 21% share price gain to ₹101, the stock is trading at a trailing P/E ratio of 24.9x, up from the previous P/E ratio of 20.7x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past year are 8.5%. Announcement • Jul 31
ZIM Laboratories Limited to Report Q1, 2021 Results on Aug 04, 2020 ZIM Laboratories Limited announced that they will report Q1, 2021 results on Aug 04, 2020 Announcement • Jul 30
ZIM Laboratories Limited (BSE:541400) completed the acquisition of an unknown minority stake in ZIM Health Technologies Limited from existing shareholders. ZIM Laboratories Limited (BSE:541400) agreed to acquire an unknown minority stake in ZIM Health Technologies Limited from existing shareholders on May 16, 2019. In a related transaction, ZIM Laboratories Limited will acquire issue of equity shares by ZIM Health Technologies Limited. Upon completion of the transaction and private placement, ZIM Health Technologies Limited will become wholly owned subsidiary of ZIM Laboratories Limited.
ZIM Laboratories Limited (BSE:541400) completed the acquisition of an unknown minority stake in ZIM Health Technologies Limited from existing shareholders in the quarter ended on June 30, 2019. 
